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Background: Recent advances have revealed a significant contribution of chemokines and their receptors in tumor
growth, survival after chemotherapy, and organ-specific metastasis. The CXC chemokine receptor-7 (CXCR7) is the
latest chemokine receptor implicated in cancer. Although over expressed in breast cancer cell lines and tumor tissues,
its mechanism of action in breast cancer (BrCa) growth and metastasis is unclear. Studies in other cancers have
implicated CXCR7 in cell proliferation, anti-apoptotic activity and cell-cell adhesion. The present study was initiated
to examine the pattern of CXCR7 expression and its role in regulation of growth signaling in breast cancer.
Methods: The contribution of CXCR7 in BrCa cell proliferation was investigated in representative cell lines using
real time quantitative PCR (q-PCR), proliferation assays, immunohistochemistry and immunoblotting. Phenotypic
changes were examined after CXCR7 specific cDNA and siRNA transfection and expression levels were monitored
by q-PCR. Further, the association of CXCR7 with epidermal growth factor receptor (EGFR) and modulation of its activity
were investigated by western blotting, immunofluorescence, and in-situ proximity ligation assays in human BrCa cells
and tissues.
Results: CXCR7 was expressed in both, estrogen receptor (ER) positive and negative BrCa cell lines. CXCR7 was also
expressed unevenly in normal breast tissues and to a much higher extent in ER + cancer tissues. Depletion of CXCR7 in
MCF7 BrCa cells by RNA interference decreased proliferation and caused cell cycle arrest. Further, proximity ligation
assay (PLA) revealed colocalization of CXCR7 with EGFR in cancer tissues and cancer cell lines. CXCR7 depletion
reduced levels of phospho-EGFR at Tyrosine1110 after EGF-stimulation and also reduced phosphorylation of ERK1/2,
indicating a potentially direct impact on mitogenic signaling in MCF7 cells. Using siRNA to knockdown β-arrestin2 in
cells with EGFR over expression we were able to nearly deplete the CXCR7-EGFR colocalization events, suggesting that
β-arrestin2 acts as a scaffold to enhance CXCR7 dependent activation of EGFR after EGF stimulation.
Conclusions: These results demonstrate coupling of CXCR7 with EGFR to regulate proliferation of BrCa cells and
suggest an important ligand-independent role of CXCR7 in BrCa growth. Thus, the CXCR7-EGFR axis is a promising
target for breast cancer therapy.
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CXCR7 is a seven-transmembrane receptor that binds
chemokines CXCL11/ITAC, CXCL12/SDF-1a, and macro-
phage migratory inhibitory factor (MIF) [1,2]. CXCR7 can
form homo-dimers and hetero-dimerize with CXCR4
[3,4]. CXCR7 binding to the chemokine SDF-1a induces a* Correspondence: blokeshw@med.miami.edu
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unless otherwise stated.gradient shift critical for correct development and primor-
dial germ cell migration which led to its reputation as a
scavenger receptor [5]. CXCR7 is considered an atypical
chemokine receptor for several important reasons. It has a
modified amino acid motif (DRYLAIV) at the second
intracellular loop, which prevents it from coupling to
G-proteins and inducing intracellular Ca2+ mobilization
[6,7]. Therefore, CXCR7 does not signal through the clas-
sical G-protein coupled receptor (GPCR) mechanism of
secondary messengers. Instead it has been shown to inter-
act with β-arrestin2 (β-AR2) as an accessory protein in aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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onto the phosphorylated cytoplasmic tail of an activated
receptor, thus preventing further activation or down-
stream signaling, because they block the G proteins from
docking onto the receptor. β-arrestins may play other
roles by acting as scaffolds. The arrestin scaffolds may
serve as adapter molecules to assemble multi-protein
complexes ultimately leading to receptor internalization,
recycling back to the plasma membrane, and downstream
signaling events, including ERK1/2 (extracellular signal-
regulated kinases) activation [9-11]. Arrestins may also
shuttle between the cell nucleus and cytoplasm [12]. This
process is not fully elucidated for CXCR7.
The behavior of CXCR7 is tissue and context dependent.
It plays an important role in development and potentially
in the progression of cancer to the metastatic stage.
CXCR7 has been found to be expressed in human breast,
lung, and prostate cancers in a stage-and grade specific
pattern [13,14]. Increased expression of CXCR7 is at-
tributed to IL-8 (Interleukin-8), inactivation of HIC1
(hypermethylated in cancer-1), activation of HIF-1α
(hypoxia-inducible factor-1), and activation of NF-kB
(nuclear factor kappa B) [15-20].
The regulation of BrCa growth by chemokine receptor
and growth factor receptor interaction is a relatively nas-
cent area of research. The innate heterogeneity of BrCa
adds to its complexity, therefore proliferation mechanisms
may be altered during cancer progression. CXCR7 or other
relevant proteins may contribute to proliferation and may
be significant targets for improved cancer therapy.
In this study we show that CXCR7 is an important
modulator of cell proliferation and cell cycle progression
of CXCR7-expressing BrCa cells. We demonstrate that
in BrCa, CXCR7 co-localizes with EGFR and CD31. We
show that down-regulation of CXCR7 affects the phos-
phorylation status of EGFR and partially decreases the
phosphorylation of key mediators of the MAPK (mito-
gen-activated protein kinases) cascade leading to cell
cycle arrest. We also show that CXCR7 interacts with
EGFR in BrCa tissue and that in some BrCa cells this
relationship may significantly contribute to BrCa pro-
liferation in a ligand independent fashion in concert
with β-AR2.
Results
CXCR7 is expressed across breast cancer cell lines
We performed q-PCR to evaluate the expression level of
CXCR7 in breast cancer cell lines. Table 1 shows CXCR7
mRNA expression relative to the housekeeping gene
PPIA. We also included CXCR4 mRNA expression for
comparison of levels of CXCR4 vs CXCR7. The cell lines
are categorized as previously described by Neve et al. [21].
CXCR7 is considered over-expressed (>2 fold difference)
across established BrCa cell lines when compared tonormal epithelial breast cell line MCF12A or MCF10A.
CXCR7 was expressed in both estrogen receptor positive
(ER+) (MCF7, T47D, BT474 and HCC 202) and estrogen
receptor negative (ER-) (HCC1954, HCC1569) cells. How-
ever, CXCR7 expression was highest in the ER + luminal
cells. CXCR7 was expressed by HER2 over-expressing
BT474 cells, however, not expressed in HER2 over-
expressing SkBr3 cells. Moreover, CXCR7 was expressed
at a low level in the aggressive post-EMT cell line MDA-
MB231. Confocal microscopy and Western blot analysis
were performed to validate expression of CXCR7 in breast
cancer cells at the protein level in the most common cell
lines (Figure 1). The breast cancer cell lines MCF7 and
BT474 showed the highest CXCR7 expression at both
mRNA and protein level compared to the normal epithe-
lial cell line MCF12A. No CXCR7 protein expression was
observed in T47D and SKBR3 cells. EGFR protein expres-
sion was also assessed to compare to CXCR7 protein
expression. No EGFR was detected in T47D and SKBR3
cells and CXCR4 was expressed across all BrCa lines
tested.CXCR7 expression affects proliferation of breast cancer
cells in a ligand and co-receptor independent manner
Since CXCR7 was abundantly expressed in several ER +
BrCa cells, we investigated the role of CXCR7 in breast
cancer cell proliferation. We down regulated CXCR7 ex-
pression using RNA interference. Transient transfection
of CXCR7 siRNA resulted in an 80 ± 5% decrease of
mRNA levels as quantified by q-PCR, i.e. the Ct differ-
ence averaged 2.18 for MCF7 siRNA control (Ct 19.95)
vs MCF7 siCXCR7 (Ct 22.13) in MCF7 cells. Protein ex-
pression was quantified using densitometry software.
Figure 2F shows the siCXCR7 lane with an 86% decrease
in CXCR7 protein expression compared to the siRNA
control lane. The stable shRNA CXCR7 levels averaged
approximately 50% less CXCR7 protein expression than
the shRNA vector control. CXCR7 down regulation re-
sulted in a 67% decrease of clonogenic growth (Figure 2B),
and decreased cell proliferation in stably transfected cell
lines (Figure 2A-B). To assess whether CXCR7 cooper-
ates with its known co-receptor CXCR4 to mediate
proliferation we used siRNA to knockdown CXCR4
expression. We observed significant decreased prolifera-
tion only after CXCR7 knockdown and increased prolif-
eration with CXCR7 over expression (Figure 2C). Down
regulation of CXCR4 had no significant decrease on
proliferation compared to control. Down regulation of
CXCR7 in BT474 cells also resulted in decreased cell
proliferation. We also over expressed CXCR7 in a cell
line with low endogenous CXCR7, MDA-MB231, where
over expression of CXCR7 resulted in increased cell
proliferation (Figure 2D).
Table 1 CXCR7 and CXCR4 mRNA level relative to PPIA (FD)
Cell line ER PR HER2 Tumor type Classification CXCR7 CXCR4
MCF10A* - - - F Basal B 0.07 0.03
MCF12A* - - - F Basal B 0.01 0.47
MCF7 + + - IDC Luminal 0.53 0.03
T47D + + - IDC Luminal 0.04 0.06
BT474 + + + IDC Luminal 0.94 0.20
SKBR3 - - + AC Luminal 0.00 0.19
MDAMB231 - - - AC Basal B 0.04 0.19
HCC202 - - + Duc Ca Luminal 0.15 0.07
HCC 1569 - - + MC Basal 0.02 0.03
HCC 1954 - - + Duc Ca Basal A 0.03 0.03
CXCR7 and CXCR4 mRNA expression relative to PPIA expression was analyzed by q-PCR. The cell line classification based on estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor receptor 2 (HER2) status was also included in this table as previously described in the literature [21].
*immortalized normal epithelial cells.
F = Fibrocystic disease.
IDC = invasive ductal carcinoma.
AC = adenocarcinoma.
MC = metastatic carcinoma.
Duc Ca = Ductal carcinoma.
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To elucidate the inhibition of proliferation following
CXCR7 down-regulation, we performed cell cycle phase
fractionation analysis of propidium iodide labeled cells
using flow cytometry. The results showed significant in-
crease in the G0/G1 fraction (33%) and a significant de-
crease in the S-phase fraction in siCXCR7 MCF7 cells
compared to control siRNA-transfected cells (Figure 2E).
Importantly, CXCR7 down regulation led to marked
changes in key proteins involved in regulating the cell
cycle. CXCR7 depletion in MCF7 cells affected the levels
of proteins regulating the S-phase transition and prolif-
eration. The proliferative markers Cyclin B1 and Cdk4
decreased, while S-phase inhibitory protein, p21 was
dramatically increased in CXCR7 depleted cells (Figure 2F).
To test whether CXCR7 depletion had an effect on apop-
tosis, we used cell surface annexin-V labeling. Results of
annexin-V binding assays on CXCR7 depleted cultures at
48 h and 72 h following siRNA transfection showed that
down regulation of CXCR7 (CXCR7siRNA) did not induce
apoptosis compared to cells transfected with control
siRNA (Data not shown).
Ligand independent effect of CXCR7
We hypothesized that CXCR7 induces proliferation in
CXCR7 expressing cells due to ligand-mediated activa-
tion of the mitogenic pathway. To test this hypothesis,
MCF7 cell cultures were starved of growth factors for
24 h and then stimulated with ITAC, SDF-1a, or EGF.
Proliferation was evaluated 48 h later. As shown in
Figure 3A, no significant increase in cell numbers were
observed between untreated and ITAC or SDF-1a treatedcultures. ITAC stimulation only marginally decreased
proliferation. However, a significant increase in growth
was observed in cultures treated with positive controls,
estrogen (E2) or combination of estrogen with epider-
mal growth factor (E2 + EGF). It has been reported that
MCF7 cells produce the CXCR7 ligand SDF-1a in an
estrogen-dependent manner [22]. To verify whether en-
dogenous SDF-1a induces CXCR7 mediated proliferation,
we transfected the cells with siRNA against SDF-1a, incu-
bated them in presence or absence of SDF-1a and then
assessed proliferation. Down regulation of SDF-1a caused
no significant changes in cell proliferation (Figure 3B), nei-
ther did supplementation with SDF-1a cause increased
growth. To determine if the non-canonical ligand MIF
had a proliferation effect mediated through CXCR7, we
added a specific inhibitor of MIF, 4-IPP, to breast can-
cer cell lines with distinct CXCR7 levels. As shown in
Figure 3C, we found that 4-IPP inhibited growth of all
tested cell lines. However, we found no association of
4-IPP cytotoxicity with CXCR7 expression. For example,
4-IPP was toxic to both MCF7 cells and CXCR7-depleted
(shCXCR7) MCF7 cells. Similarly, it was cytotoxic to
MB231 which express low levels of CXCR7 (Figure 3C).
We investigated the relative proliferation levels of MCF7
cells with stable expression of vector shRNA (shC, control)
and shCXCR7 (shR7) in the presence of EGF (10 ng/mL)
for 72 hrs by counting the cells at the end of incubation. In
the control cells there was a marginal increase in prolifera-
tion in EGF stimulated cells vs non stimulated cells, as seen
in Figure 3A. In cells with CXCR7 depletion, shR7, there
was no apparent or significant increase in EGF stimulated
vs non stimulated shCXCR7 cells (Figure 3D).
Figure 1 Validation of CXCR7 expression in BrCa cell line lines through immunofluorescence and western blot analysis. Panel A. CXCR7
protein expression (green fluorescence) was detected through immunofluorescence across some of the most commonly used BrCa cell lines.
Panel B. In parallel experiments, cells were seeded in cell culture plates and 24 h later cells were lysed, proteins were collected and quantified and
CXCR7, CXCR4, and EGFR expression was analyzed by Western blot analysis as described in Material and Methods. Actin served as a loading control.
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breast cancer cell line MCF7 and breast cancer tissue
Since CXCR7 affects proliferation in BrCa cells independ-
ently of its ligands and co-receptor CXCR4, we aimed to
evaluate which proteins associate with CXCR7 and partici-
pate in CXCR7 mediated proliferation. We first evaluated
co-localization/interaction of CXCR7 and EGFR in MCF7
cells. We performed a specific immunofluorescence ap-
proach, an in-cell co-immunoprecipitation assay, also
known as a proximity ligation assay (PLA). Figure 4 dem-
onstrates co-localization of CXCR7 with EGFR in MCF7
cells. Figure 4B shows co-localization of CXCR7 and
EGFR in the absence of 10 ng/ml EGF stimulation. How-
ever, the CXCR7-EGFR co-localization was dramatically
increased upon stimulation with EGF for 2–5 minutes(Figure 4C). Furthermore, we used an EGFR plasmid to
minimally over express EGFR as MCF7 cells express a
relatively low level of EGFR and observed a further in-
crease of CXCR7-EGFR co-localization compared to
negative controls (Figure 4D). Using immunofluorescence
(IF), we also found that CXCR7 and EGFR co-localized
strongly in breast cancer tissue compared to normal
breast tissue (Figure 4E-F). We went futher to analyze for
CXCR7-EGFR co-localization events in human breast tis-
sue using the PLA. We confirmed an increased CXCR7-
EGFR interaction in human ER + breast cancer tissues
compared to normal breast tissues (Figure 4G-H). As
CXCR7 is known to be expressed in endothelial cells and
tumor associated vasculature of bladder and prostate can-
cers, we verified the expression of CXCR7 in the context
Figure 2 CXCR7 depletion in MCF7 cells affects breast cancer cell proliferation. A. The clonogenic potential of CXCR7 depleted MCF7 cells
was analyzed in colony forming assays. The insert shows colony formation in CXCR7 depleted (stably shCXCR7 (shr7) transfected cells, right well)
compared to vector control transfected cells (shC) (left well). B. Cell proliferation of MCF7 cells with stable CXCR7 depletion (shCXCR7 clone,
(shR7)) compared to control cells (shC). C. Effect of CXCR7- (siR7) and CXCR4- (siR4) down regulation and CXCR7 (R7) over expression on proliferation
of MCF7 cells. D. Proliferation of CXCR7 depleted (siR7) BT474 cells and CXCR7 over expressing (R7) MB231 cells compared to corresponding controls
(siC = control siRNA, C = empty plasmid control). E. Cell cycle arrest of cells with down regulated CXCR7. F. Analysis of relevant cell cycle
markers following siRNA mediated down regulation of CXCR7. Asterisks indicate statistical significance, P < 0.05.
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used IF to evaluate expression and co-localization of
endothelial cell marker CD31 with CXCR7 in human
breast tissue. Additional file 1: Figure S1 shows that
CXCR7 co-localizes with CD31, which is consistent with
its reported expression in endothelium. Moreover, in
order to assess whether CXCR7 expression is aberrant in
the breast tumor microenvironment vs. normal tissue, we
used the Oncomine data base to query. Our analysis using
the Ma Breast 4 database [23] indicates that CXCR7 ex-
pression is higher in breast cancer tissue stroma compared
to normal breast tissue stroma.
Down regulation of CXCR7 decreases levels of p-ERK and
p-EGFR in MCF7 cells
To assess whether down regulation of CXCR7 affected
the mitogenic pathway, we assessed for changes in the
MAPK/ERK kinase cascades. Since ERK1/2 is classically
involved in cell proliferation and differentiation of many
cell types, and is the last step in this cascade of events,we analyzed for its expression. The inhibition of CXCR7
by siRNA resulted in decreased ERK1/2 phosphorylation in
EGF (10 ng/mL, 2 min) stimulated MCF7 cells (Figure 5A).
We also stimulated with SDF-1a, but were not able
to observe ERK1/2 activation (data not shown). Since
EGFR is a known mitogenic driver of cell proliferation
and we demonstrated co-localization between CXCR7
and EGFR earlier, we next analyzed whether EGFR
activation was also affected by CXCR7 depletion.
Down regulation of CXCR7 decreased activation of
EGFR at Tyrosine1110 compared to control siRNA
transfected cells; quantification of EGFRY1110/EGFR
total ratio for EGF stimulated cells in bar graphs under-
neath blots (Figure 5C). Furthermore, we confirmed these
results in EGFR over expressing cells. CXCR7 depletion
(siCXCR7) decreased phosphorylation at the Tyrosine1110
site in EGFR of over expressing-MCF7 cells, compared to
cells over expressing EGFR alone, demonstrating a signifi-
cant role of CXCR7 in EGFR activation (Additional file 2:
Figure S2).
Figure 3 CXCR7 ligand independent effect. A. MCF7 cells were stimulated with CXCR7 ligands CXCL11 (ITAC), CXCL12 (SDF-1a) and proliferation
was evaluated. A significant increase in growth was observed in cultures treated with positive controls, estrogen (E2) or combination of estrogen with
epidermal growth factor (E2 + EGF). B. Effect of endogenous and external added SDF-1a on MCF7 cell proliferation. Rescue of potential SDF-1a mediated
autocrine activation of CXCR7 using siRNA to down regulate endogenous SDF1a (siSDF-1) compared to control siRNA (siC) and addition of external
SDF-1a to media (+SDF-1); ns: no statistical difference. C. Percent survival of cells based on quantification of optical density measurements of
cells treated 4-IPP, a specific MIF inhibitor for 48 hrs. MTT assay was used for viability estimation. D. Proliferation experiments comparing the
stable line MCF7 vector shRNA control (shC) and shCXCR7 (shR7) treated with EGF (10 ng/mL) for 72 hrs. Data presented from one representative
experiment with triplicate determination of cell numbers.
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phosphorylation of EGFR and ERK
CXCR7 is known to signal through β-arrestin2 in a var-
iety of cell types including rat vascular smooth muscle
cells, mouse medial ganglionic eminence interneurons,
HEK cells, and normal human epidermal melanocytes
[8,24-26]. To evaluate the role of the CXCR7/β-AR2 axis
in the EGFR mediated mitogenic pathway, we over
expressed β-AR2 in MCF7 cells, which express a rela-
tively low basal level of β-AR2. We over expressed β-
AR2 in the presence or absence of CXCR7 siRNA and
analyzed phosphorylation levels of ERK and EGFR. Our
studies show increased phosphorylation of ERK1/2 and
EGFR at Y1110 in β-AR2 over-expressing cells. However,
with CXCR7 down regulation, we observed a significant de-
crease in phosphorylation of both ERK1/2 and EGFRY1110
even after β-AR2 over expression (Figure 5B,D). In order to
visualize whether β-AR2 is involved in the colocalization of
CXCR7-EGFR, we used siRNA to down regulate β-AR2,
followed by EGF stimulation and PLA to assess the level of
CXCR7-EGFR heterodimerization. As MCF7 cells express
relatively low levels of EGFR, we concomitantly employed a
pLPCX-vector construct to over express EGFR. Non-
specific isotype control antibodies were used as negative
control (Figure 5E). EGFR over expressing cells showed a
dramatic increase of CXCR7-EGFR co-localization com-
pared to non-transfected cells (Figure 5F). However, siRNAmediated knockdown of β-AR2 in EGFR overexpressing
MCF7 cells resulted in an almost complete loss of CXCR7-
EGFR colocalization events (Figure 5G). Similarly, down
regulation of CXCR7 via siRNA as a control, significantly
diminished CXCR7-EGFR colocalization (Figure 5H).
Discussion
CXCR7 is expressed across breast cancer cell lines
We observed that cell lines with higher expression of
CXCR7 are also estrogen receptor positive (ER+) and
of luminal cell origin. We also observed that CXCR7
mRNA expression was distinct from CXCR4 mRNA
expression when normalized to a house-keeping gene
PPIA. Protein expression does not always correlate with
mRNA level, therefore we cannot assume that the pro-
tein level of CXCR7 is also higher than that of CXCR4
in the same cell line when comparing the intensity of
specific bands in immunoblots as band intensity is
dependent on the affinities of the antibody used for
probing the protein, e.g., CXCR4 vs CXCR7. In tissues,
CXCR7 expression was mostly restricted to the luminal
layer of breast ducts in normal breast tissue and was
highly over expressed in tumor tissue. Boudot et al.
showed that the CXCR7 axis is under the control of the
estrogen receptor and that CXCR7 expression is de-
creased upon addition of estrogen to MCF7 cells [22]. It
is important to consider that many of the breast tumors
Figure 4 CXCR7 co-localizes with EGFR. A-D. After fixation of
MCF7 cells, PLA (in situ co-immunoprecipitation) was performed
with specific CXCR7 [GTX100027, (1:500), GeneTex, Irvine, CA] and
EGFR antibodies [E2760, (1:500), Sigma Aldrich, St. Louis, MO] to
visualize heterodimerization of CXCR7 with EGFR. Colocalization is
shown as a red fluorescent PLA signal (CX7/EGFR), and nuclei were
counterstained with DAPI (blue) (630x magnification). As the PLA
technique requires two specific antibodies to give a red fluorescent
signal we used a single primary antibody as a negative signal control.
A. Negative controls experiment using EGFR antibody alone. B. Basal
level of CXCR7-EGFR colocalization in non-stimulated MCF7 cells. C.
CXCR7-EGFR colocalization in MCF7 cells stimulated for 2 min with EGF
(10 ng/mL). D. CXCR7-EGFR colocalization in EGFR over expressing
(O.E.) MCF7 cells following 2 min EGF (10 ng/mL) stimulation.
E. Immunofluorescence of normal human breast tissue for detection of
CXCR7 (green fluorescence) and EGFR (red fluorescence) (400×
magnification). F. Immunofluorescence of ER + breast cancer tissue
stained as explained in E. G. PLA of normal human breast tissue using
CXCR7 and EGFR antibodies to visualize colocalization of CXCR7 with
EGFR (CX7/EGFR), nuclei were counterstained with DAPI; 400×
magnification. H. PLA of ER + human breast tumor tissue stained
as explained in G.
Figure 5 β-arrestin2 plays a role in CXCR7 mediated
phosphorylation of EGFR and ERK. A. Levels of pERK1/2 and total
ERK in MCF7 cells transfected with siCXR7 or control siRNA (C). ERK
levels were determined by Western blotting of cell lysates prepared
from serum-starved cells stimulated with EGF (10 ng/mL) for 5 minutes.
B. The ratio of p-ERK1/2 over total ERK1/2 in western blot was
quantified from analysis of MCF7 cell lysates that were transfected with
control plasmid (cDNA), β-arrestin2 (βAR2) or β-arrestin2 in combination
with siCXR7 (βAR2siR7) and stimulated with EGF (+). C. CXCR7 down
regulation via siRNA decreased activation of EGFR at Tyrosine 1110 in
MCF7 cells. D. The ratio of p-EGFRY1110 over total EGFR was quantified
in cells transfected with control plasmid (cDNA), β-arrestin2 (βAR2),
or β-arrestin2 in combination with siCXR7 (βAR2siR7) and stimulated
with EGF (+). The western blot experiments were repeated twice and
one representative experiment is shown. E-H. Following transfection
with EGFR-WT plasmid for EGFR over expression (O.E.), PLA was
performed in MCF7 cells to visualize heterodimerization of CXCR7
with EGFR after 5 min EGF (10 ng/mL) stimulation; nuclei were
counterstained with DAPI (blue). E Incubation with non-specific
isotype antibody (negative control). F. PLA signal indicating
CXCR7/EGFR dimers in non-stimulated MCF-7 cells. G. PLA signal
indicating CXCR7/EGFR dimers in MCF7 cells transfected with
EGFR-WT plasmid and siRNA against βarrestin2. H. CXCR7/EGFR
dimers in MCF7 cells transfected with EGFR-WT plasmid and siRNA
against CXCR7 (630x).
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consistently found CXCR7 over expression predomin-
antly in ER + cells, thus exploring CXCR7’s role in me-
tastasis independently of CXCR4 is highly relevant [28].
Moreover, EGFR expression correlated with CXCR7
expression across breast cancer cell lines and no EGFR
expression was observed in the cell lines that lack
CXCR7 protein expression. This may support the role of
the heterotypic and unique CXCR7-EGFR interaction in
breast cancer proliferation.
Down regulation of CXCR7 decreases growth of breast
cancer cells
Clonogenic assays showed a significantly slowed repro-
ductive potential of CXCR7 depleted MCF7 cells com-
pared to control cells (Figure 2A, inset). We confirmed
the role of CXCR7 in proliferation in different breast
cancer cell lines and found significantly decreased prolifer-
ation following CXCR7 down regulation, whereas CXCR7
over expression resulted in an increased proliferation.
Consistently, the role of CXCR7 in proliferation has been
previously described for other tumor entities, such as
prostate cancer [13]. Reduced expression of CXCR7 coin-
cided with an inhibition of cell cycle progression and
marked changes in key proteins involved in cell cycle
regulation. Cell cycle arrest at the G2/M checkpoint is
characterized by increased p21 expression which prevents
formation of the Cyclin B/Cdk1 complex necessary for
cells to go through mitosis [29]. We observed that CXCR7
depletion increased p21 and decreased Cyclin B1 accu-
mulation, thus preventing the tumor cells from divid-
ing. Consistently, Singh and Lokeshwar showed that
down regulation of CXCR7 in prostate cancer cells re-
sulted in similar reduced Cyclin B1 and increased p21
expression [15].
CXCR7 affects BrCa proliferation in a ligand-independent
fashion
MCF7 cells endogenously express the ligand for CXCR7,
SDF-1a [30,31]. Interestingly, this endogenous ligand
production is not substantial enough to trigger autocrine
downstream events [1]. However, the ligand-independent
role of CXCR7 has not been explored in breast cancer.
Our results demonstrate that SDF-1a did not increase
MCF7 cell proliferation, supporting the conclusion that the
effect of CXCR7 in these BrCa cells is ligand independent.
However, in vivo, CXCL12 ligand may be expressed at
higher levels than those observed in cell cultures [32,33]
and small molecular competitive inhibitors of CXCR7, such
as antagonists of SDF-1a binding have been shown to
decrease tumor growth in lymphoma and lung carcin-
oma [1]. We also addressed the possibility of a non-
canonical ligand of CXCR7, MIF, having an effect on
proliferation. MIF is likely a stromal component of thetumor microenvironment, therefore, it is possible that
a MIF inhibitor did not have specific cytotoxicity but
non-specific cytotoxicity. However, similar to the ef-
fects of SDF-1a, it is likely that in vivo, stromal compo-
nents may change the behavior of CXCR7 significantly.
Furthermore, we conducted proliferation studies with
and without EGF treatment in cells with control (shC)
and low (shR7) CXCR7 levels to assess for the proliferative
effects of EGF on our postulated CXCR7-EGFR interaction.
We confirmed that following CXCR7 depletion in MCF7
cells with ~50% stable CXCR7 down regulation, prolifera-
tive stimulation of EGF was limited.CXCR7 affects BrCa proliferation in a CXCR4 independent
fashion
Previous studies have shown that elevated expression
and function of CXCR4 have significant effects on
survival, proliferation and metastasis of BrCa [34,35].
CXCR7 has also been directly linked to metastasis
through its interaction with CXCR4 [1,13,28,36,37]. In
some cells it has been shown that CXCR7 and CXCR4
cooperate to mediate signaling and we aimed to investi-
gate whether this is the case in breast cancer cell lines
[26,38]. Our results demonstrate that down regulation of
the CXCR7 receptor resulted in a significant decrease in
proliferation. In contrast, decreased expression of CXCR4
appears to increase proliferation to levels near those ob-
served by CXCR7 over-expression, however, the effects
were not statistically significant (Figure 2C). CXCR7 and
CXCR4 levels are closely regulated across cell lines and
CXCR7 is known to affect the stability of CXCR4 [39],
therefore it is likely that expression levels of one receptor
affect the other. However, since our results demonstrate
that solely CXCR7 expression had a consistently signifi-
cant effect on proliferation, we can infer the distinctive
and co-receptor independent effect of CXCR7 in MCF7
cell proliferation.CXCR7 interacts with EGFR in human breast cancer cell
lines and tissues
Several reports have linked CXCR7 with other marker
proteins including CD31 and EGFR [15,32,37]. Our re-
sults demonstrate for the first time that CXCR7 interacts
with EGFR in human breast cancer cell lines and that
CXCR7-EGFR co-localization is significantly increased
upon EGFR over expression. To corroborate our results
and evaluate its clinical significance, we analyzed human
breast samples for colocalization of CXCR7 and EGFR.
We observed a significant increase in receptor colocali-
zation in human ER + breast cancer tissues compared to
normal breast tissues suggesting an important role of
the CXCR7-EGFR association in ER + breast tumor cell
proliferation.
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Furthermore, CXCR7 is known to be expressed in endo-
thelial cells and tumor associated vasculature [13,40].
Consistently, we show that CXCR7 co-localizes with the
endothelial cell marker CD31 in breast tumor vessels.
This is also in accordance with analysis of the Oncomine
database which identifies CXCR7 as over expressed in
breast tumor associated stroma when compared to normal
tissue stroma (Additional file 1: Figure S1). Expression of
CXCR7 in the tumor associated vasculature and stroma
suggests a role in endothelial cell proliferation and under-
lines the importance of CXCR7 for tumor growth and
microenvironment.Down regulation of CXCR7 decreases ERK1/2 and EGFR
activation
Seven transmembrane receptors have been shown to
heterodimerize with ERBB family members and studies
have demonstrated that the CXCR7 co-receptor CXCR4
interacts with EGFR in other types of cancer, like tumors
of the prostate and bladder [37,41]. EGFR is also known
to be transactivated by seven transmembrane receptors
to regulate events such as ERK signaling and prolifera-
tion [10]. We found that down regulation of CXCR7
decreased the level of activation of phospho-EGFR and
phosho-ERK1/2, which suggests a strong association of
CXCR7 with EGFR in breast cancer in accordance with
our in situ co-IP data and confirms a role of CXCR7 in
EGFR mediated ERK signaling. Additionally, our studies
using RNA interference indicate that disruption of the
CXCR7-EGFR interaction following down regulation of
CXCR7 not only affects the phosphorylation activity of
EGFR and ERK1/2 but leads to cell cycle arrest and
decreased cell proliferation.Figure 6 A model of CXCR7-EGFR Interaction. CXCR7 signals
through β-arrestin2, which mediates interaction of CXCR7 with EGFR and
activation of EGFR mediated signaling. In some instances CXCR7 might
activate mitogenic signaling independently from EGFR (and vice versa).
This EGFR transactivation, which occurs in a CXCR7-ligand independent
fashion, induces proliferation effects in breast cancer cells.CXCR7 affects phosphorylation of EGFR and ERK via
β-Arrestin2
Following binding of SDF-1a, CXCR7 preferentially in-
duces signaling events via interaction with β-AR2 [8].
β-arrestins can interact directly with component kinases
of the extracellular signal regulated kinase ERK/MAPK
cascades leading to metastable β-arrestin complexes with
ERK1/2 [9,42]. β-arrestins are also relevant in breast
cancer progression, particularly β-AR2 which is expressed
across both, luminal and basal breast cell lines [43]. How-
ever, it was not clear yet whether β-arrestins also mediate
ligand independent CXCR7 signaling. Therefore it was
necessary to determine whether CXCR7 affects the mito-
genic pathway via interaction with EGFR directly or indir-
ectly through β-AR2. Our phosphorylation studies show
an increased phosphorylation of ERK1/2 and EGFR at
Y1110 in β-AR2 over expressing cells. Importantly,CXCR7 down regulation resulted in a significant decrease
of phospho ERK1/2 and EGFR Y1110 even after β-AR2 over
expression. Furthermore, we found that decreasing β-AR2
expression substantially decreased the colocalization of
CXCR7-EGFR and β-AR2 thus plays a significant role in
their association. These results suggest that the CXCR7/
β-AR2 axis plays a key role in activation of EGFR and
ERK and the CXCR7-EGFR crosstalk to mediate breast
tumor proliferation.
Conclusions
In the present work we demonstrate that CXCR7 is an
important modulator of cell proliferation through regu-
lation of cell cycle progression and mitogenic activation
of CXCR7-expressing BrCa cells. Interestingly, we found
a ligand independent role of CXCR7 mediated cell
proliferation.
Our data demonstrate a significant heterotypic mo-
lecular interaction between two cell surface receptors
with relevant clinical significance. We investigated the
interaction of CXCR7 with EGFR and its role in BrCa
cell proliferation and progression. We demonstrate that
CXCR7 employs ERK1/2 mediated proliferation via the
scaffold protein β-AR2 as its aid to interact with EGFR
and offer a model for this interaction (Figure 6). New
therapeutic strategies should employ relevant CXCR7
C-terminus inhibitors, not just the currently available
ligand-like inhibitors to disrupt the CXCR7 mediated
cancer phenotype. Therefore, exploring the role of CXCR7
in BrCa progression is clinically relevant and targeting the
CXCR7-EGFR interaction might be a first line of therapy
for patients presenting with primary tumors with CXCR7
over expression.
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Cell lines and cell culture
All cell lines were obtained from an authenticated source
(ATCC, Manassas, VA) and used within six months of
resuscitation of original cultures. The cell lines used in
the study were also authenticated for their origin by
Genetica DNA Laboratories Inc (Cincinnati, OH). Cul-
ture and maintenance of BrCa cell lines were performed
by routine cell culture procedures. Cells were cultured
in RPMI 1640 medium supplemented with fetal bovine
serum (FBS, 10%) and gentamicin (10 μg/ml).The nor-
mal breast epithelial cell line, MCF10A was maintained
in MEBM medium supplemented with the additives ob-
tained from Lonza/Clonetics Corporation as a kit:
MEGM Kit Catalog No. CC-3150. The normal breast
epithelial cell line, MCF12A was maintained in DMEM/
F12 medium supplemented with the additives obtained
from Lonza/Clonetics Corporation as a kit: MEGM Kit
Catalog No. CC-3150 and 10% horse serum.
Gene knockdown with siRNA
Cells cultured for 24 h were transfected with gene-
specific 21-mer siRNA sets (Smartpool siRNA, Dharma-
con/Thermo Scientific Inc, Chicago, IL), using the
Dharmafect-2 transfection protocol.
Stable silencing of CXCR7 expression by shRNA
MCF7 shCXCR7 and vector control cell lines were made
as described before [44]. Briefly, CXCR7 shRNA and
scrambled sequence shRNA (Control shRNA) constructs
were cloned into a pRS plasmid under the control of a
U6 promoter for stable expression (HuSh-29mer, Ori-
gene Technology Inc. Baltimore, MD). Cells were trans-
fected with shRNA-pRS using Lipofectamine 2000 (In
Vitrogen Inc., Carlsbad, CA). Stable transfectants were
selected from transfected cultures following two weeks
of culture in puromycin selection medium (2.0 μg/ml).
Emergent cell colonies were evaluated for CXCR7
mRNA knockdown by q-PCR and immunoblotting.
Gene over-expression with cDNA
Cells were transfected with a human full-length CXCR7
cDNA (pCMV6-Neo vector; OriGene, Rockville, MD) or
CXCR7-green fluorescent protein (EGFP-N1 vector; BD
Biosciences, San Jose, CA), a generous gift from Dr.
Katherine Luker University of Michigan, Ann Arbor MI
[45]. EGFP-β-arrestin2 cDNA was a generous gift from
Dr. V.R. Krishna Jala (Department of Immunology, Uni-
versity of Louisville, Louisville, KY). EGFR insert was
cloned into a pLPCX plasmid under control of a CMV-
IE promoter (Clontech, Mountainview, CA). Cells were
transfected using Lipofectamine 2000 and analyzed for
over expression by q-PCR and immunoblotting.Cell proliferation assay and cell cycle phase analysis
Cell proliferation and cell viability were determined by cell
counting and MTT reduction assays, respectively. Cell cycle
phase-fractionation was conducted using preparations of
propidium iodide labeled nuclear suspension analyzed on a
Beckman-Coulter XCEL flow cytometer as described before
[46]. The MIF inhibitor used for cell proliferation was 4-
IPP (Tocris Bioscience Cat. No. 3429).
Quantitative real time PCR (q-PCR)
Total RNA isolated from cells 48 h later was subjected
to cDNA synthesis and q-PCR using iQ SYBR-Green
Supermix (Bio-Rad, Hercules, CA) and the primers de-
scribed in Additional file 3: Table S1 (Supplement).
The mRNA levels were normalized to that of the
housekeeping protein, peptidylprolyl isomerase A
(PPIA) based on the threshold cycle (Ct) of each sam-
ple in RT q-PCR. Relative levels of mRNA expression
were calculated from ΔCt where ΔCt = (test mRNA Ct-
PPIA Ct). Values are shown as fold difference (FD), de-
fined as FD = (2ΔCt)−1 × 100).
Immunoblotting
Expression of specific proteins in treated cells was ana-
lyzed by routine immune-blotting technique. Briefly,
proteins were quantified using Micro BCATM Protein
Assay Kit (# 23235, Thermo Scientific, Lafayette, CO)
and equal amounts of proteins were loaded and sepa-
rated on 10% SDS acrylamide gels and blotted onto
PVDF Immobilon-P Membrane (EMD Millipore, Billerica,
MA). Presence of specific proteins on the membranes was
detected using specific antibodies and the ECL + Kit (GE
Health Science). Relative protein band intensities were
quantified using densitometry (Gel Logic 2200, Care-
Stream Instruments, Rochester, NY). Band densities were
normalized to those of actin.
Antibodies
Antibodies used as described in [15] for cell cycle ana-
lysis and isotype controls; in addition, specific antibodies
used are: CXCR7 Ab (GTX1000027, GeneTex, Irvine,
CA) for confocal at 1:500; CXCR7 Ab (20423-1AP, Pro-
teintech Group, Chicago, IL) 1:5000 for immunoblotting;
EGFR Ab (E2760, Sigma Aldrich, St. Louis, MO) for
confocal 1:500; EGFR Ab (Cell Signaling 2646S, Beverly,
MA) for western blotting at 1:3000; phospho-EGFRY1110
Ab (2284–1, Epitomics, Cambridge, MA) for western
blotting 1:1000; β-arrestin2 Ab (sc-13140, Santa Cruz,
Dallas, TX) for western blotting 1:500.
Tissue specimens
Resected human breast tissues were obtained with pa-
tient’s informed consent and were fixed in formalin, par-
affin embedded and sectioned under an approved
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Miami, FL. All specimens used in this study were
blinded to protect patient identities as per HIPPA and
IRB regulations.
Proximity ligation assay
Proximity Ligation Assay (PLA), also called in-cell co-IP
assay, by Olink Bioscience (Sweden), was used to identify
specific colocalization events of CXCR7 and EGFR in
fixed cells or tissues. Prior to the PLA, cells were fixed
in 4% paraformaldehyde at 4°C, 15 minutes and human
breast tissues were de-waxed. Cells and tissue were incu-
bated with anti-CXCR7 rabbit IgG (1:500, GeneTex) and
anti-EGFR mouse monoclonal antibody (1:500, Sigma)
or normal rabbit IgG. Following incubation with primary
antibody, cells were incubated with corresponding sec-
ondary antibodies that were conjugated with oligonucle-
otides (PLA probe MINUS and PLA probe PLUS). Then,
ligation solution was added, consisting of ligase and two
oligonucleotides that hybridize to the two PLA probes
and form a closed circle if the PLA probes are in close
enough proximity. Strand extension by rolling circle
amplification (RCA) by T4-ligase and PCR amplification
of double hybridized DNA was performed as described
by the supplier. Fluorescently labeled oligonucleotides
were used detection of the RCA product. The resulting
signal (a red fluorescent signal of Texas-Red fluorescent
tagged amplified DNA) occurs wherever the two mole-
cules are colocalized. Quantification of the confocal im-
ages was performed using the Duolink Image Tool
software (Olink Bioscience).
Image acquisition and analyses
Cells and tissues were viewed under a Zeiss LSM 700
laser scanning confocal microscope. Images were ac-
quired at 400× to 630× magnification using 40× or 63×
oil-immersion objectives. Hardware control and acquisi-
tion of images was performed using the ZEN software.
Oncomine box plots
CXCR7 expression analysis performed using Oncomine, a
cancer microarray database and web-based data-mining
database platform [47]. We used subsequent databases
based on mRNA expression collected via Affymetrix X3P
Array. Filters were applied for differential analysis compar-
ing specific classifications of breast cancer to normal in
breast tissues. Box plots represent CXCR7 expression
changes in the Ma Breast 4 database as measured by Affy-
metrix Human X3P Array in Ma Breast 4 database.
Statistical analysis
All quantitative data shown, except the western blot quanti-
fication, were from three separate experiments each data
point representing a mean of triplicate determination.Western blots have been repeated twice. Significance of
data was analyzed with the Prism graph pad software. Im-
munohistochemistry data were independently evaluated by
two investigators.
Additional file
Additional file 1: Figure S1. CXCR7 co-localizes with CD-31 in breast
tumor associated stroma. Expression of CXCR7 and endothelial cell marker
CD31 in human breast tissue was analyzed by immunofluorescence. A. Nuclei
of human breast tissue specimen counter stained with DAPI B. CXCR7 (green
fluorescence) was mostly restricted to the luminal layer of breast ducts. C.
CD31 (red fluorescence) marks endothelium tissue D. Overlay of B and C:
CXCR7 (green fluorescence) colocalized with endothelial cell marker CD31
(red fluorescence) within the ER + breast cancer tissue. E-F. Box plots of the
Ma Breast 4 Study showing CXCR7 relative mRNA expression as measured by
Affymetrix Human X3P Array in Ma Breast 4 database comparing CXCR7 E.
In ductal breast carcinoma in situ stroma vs. normal tissue CXCR7 has an
Over-expression Gene Rank: 59 (in top 1%), P-value: 1.10E-6, t-Test: 6.304 and
Fold Change: 4.431 F. For invasive ductal breast carcinoma stroma vs. normal
tissue CXCR7 has an Over-expression Gene Rank of 125 (in top 1%), P-value:
6.08E-5, t-Test: 5.148 and Fold Change: 4.610.
Additional file 2: Figure S2. pY1110/EGFR ratio is decreased in MCF7
cells overexpressing EGFR-WT. MCF7 cells were transiently transfected
with EGFR plasmid or with both EGFR plasmid and siRNA targeting CXCR7.
CXCR7 depletion (siCXCR7) decreased phosphorylation at the Y1110 site in
EGFR over expressing MCF7 cells after EGF (10 ng/mL, 2 min).
Additional file 3: Table S1. Primer sequences used for analysis of
mRNA expression for CXCR7, CXCR4, and PPIA.
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